EGFR and neoplasm: Analysis of the cohort (n = 52) of advanced gastroesophageal cancer patients treated with palliative PBC revealed that patients with tumours containing amplified EGFR (n = 13) had longer median survival (315 days, 95% CI 183.3–446.7) than patients without EGFR CNG (201 days, 95% CI 184.1–217.9), HR 0.49, 95% CI 0.23–0.99, p = 0.041 (Fig. 1a).